{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-022197","form_type":"8-K","ticker":null,"cik":"0001522860","company_name":"Acutus Medical, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.812792+00:00","generated_at":"2026-06-02T05:42:20.781624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acutus Medical Q1 revenue up 192% to $3.6M; net loss narrows; stock delisted to OTC Pink","bullets":["Q1 continuing ops revenue $3.6M, up 192% YoY; GAAP gross margin improved to -1% from -70%.","Net loss from continuing ops $2.1M ($0.07/share) vs $4.3M ($0.15) in Q1 2023.","Cash, equivalents, marketable securities, restricted cash $20.0M at March 31, 2024.","Nasdaq commenced delisting; stock now trades on OTC Pink under AFIB as of May 9, 2024.","Company will cease providing financial guidance due to restructuring and exit from EP mapping/ablation."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-022197","json":"https://secwatch.observer/filing/0001628280-24-022197.json","markdown":"https://secwatch.observer/filing/0001628280-24-022197.md","text":"https://secwatch.observer/filing/0001628280-24-022197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1522860/000162828024022197/0001628280-24-022197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1522860/000162828024022197/afib-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:42:20.781624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ca4876b756894c0da34a7b870912b2bb6fce48e","claim":"Acutus Medical, Inc. reported the quarter ended March 31, 2024 results: revenue $3.6 million, net income $2.1 million, EPS $0.07.","evidence_excerpt":"Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024. Recent Highlights: • First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter last year. • Operating expenses for continuing operations were $3.3 million, a reduction of 38% compared to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1522860/000162828024022197/0001628280-24-022197-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.6 million"},{"label":"Net income","value":"$2.1 million"},{"label":"EPS","value":"$0.07"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}